This is a summary. To read the whole story subscribe to BostonGlobe.com
Alkermes PLC was a bright spot among the biotechs — the sector has been more than a bit volatile lately — after the company said its experimental drug to treat schizophrenia symptoms, aripiprazole lauroxil, met the main goal in a late-stage study. Patients treated once a month with either 441 or 882 milligrams had statistically significant improvement. Alkermes plans to seek FDA approval in the third quarter. Based in Dublin, Alkermes has its R&D center in Waltham.